Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung...

Introducing a novel approach to enhance checkpoint inhibitor therapy for cancer, promising improved treatment outcomes and efficacy in clinical...

Checkpoint inhibitor therapies release the immune system's molecular "brakes," removing protein barriers that hinder its ability to detect and...

Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored...

Researchers have developed a new nanomedicine therapy that delivers anticancer drugs to  lung cancer cells and enhances the immune system’s ability...

Brigham's dual-action treatment shows promise in preclinical lung cancer models, enhancing drug delivery and immune response.

Researchers have discovered metabolic markers that forecast cancer patients' immunotherapy responses and survival outcomes, highlighting the...

An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib,...

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.

In a pooled analysis of three clinical trials, acupuncture significantly reduced hot flashes and other hormonal side effects of endocrine therapy...